Net margin is calculated as Net Income divided by its Revenue. Esperion Therapeutics's Net Income for the
three
months ended in Dec. 2023 was $-56.3 Mil. Esperion Therapeutics's Revenue for the
three
months ended in Dec. 2023 was $32.3 Mil. Therefore, Esperion Therapeutics's net margin for the quarter that ended in Dec. 2023 was -174.71%.
The historical rank and industry rank for Esperion Therapeutics's Net Margin % or its related term are showing as below:
ESPR'
s Net Margin % Range Over the Past 10 Years
Min: -343.04 Med: -179.87 Max: -63.09
Current: -179.87
ESPR's Net Margin % is ranked worse than 88.43% of 1020
companies
in the Drug Manufacturers industry
Industry Median: 3.765
vs ESPR: -179.87
Esperion Therapeutics Net Margin % Historical Data
The historical data trend for Esperion Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Esperion Therapeutics Net Margin % Distribution
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's Net Margin % falls into.
Esperion Therapeutics Net Margin % Calculation
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Esperion Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Esperion Therapeutics (NAS:ESPR) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Esperion Therapeutics Net Margin % Related Terms
Thank you for viewing the detailed overview of Esperion Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Esperion Therapeutics (Esperion Therapeutics) Business Description
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ESPR has been successfully added to your 